Compare Starbucks Corp (SBUX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs TG Therapeutics Inc — how do they compare? Starbucks Corp trades at $100.32 (market cap $116.29B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Starbucks Corp is far larger — about 13.6× TG Therapeutics Inc's market cap, and Starbucks Corp pays a 2.43% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SBUX | TGTX | |
|---|---|---|
Market Cap | $116.29B | $8.53B |
Volume | 7,493,833 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $108.55 | $59.06 |
52-Week Low | $78.46 | $26.94 |
Enterprise Value | $135.12B | $8.74B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $102.01, down 2.35% today, with a bearish technical signal but strong recent earnings beats. Revenue grew to $37.18B in 2025, though net income margin compressed to 5.17%. The stock faces headwinds from high valuation multiples (P/E 58.97) and negative shareholder equity, but analyst consensus remains positive with a $113.60 price target. Recent news highlights CEO Niccol's turnaround progress and record sales from seasonal offerings.
Outlook is mixed: operational improvements and debt reduction support upside, but margin pressure and union disputes pose risks. The stock offers growth potential if execution continues, yet investors must weigh high valuation against competitive and labor challenges in the coffee retail sector.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
